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Stem cell therapy for conditions characterized by myocyte loss in myocardial infarction and heart failure is intuitively appealing.
Stem cells from various sources, including heart itself in preclinical and animal studies, have shown the potential to improve the
function of ventricular muscle after ischaemic injury. The clinical experience from worldwide studies have indicated the safety
proﬁle but with modest beneﬁts. The predominant mechanisms of transplanted cells for improving cardiac function have pointed
towards paracrine eﬀects rather than transdiﬀerentiation into cardiomyocytes. Thus, further investigations should be encouraged
towards bench side and bedside to resolve various issues for ensuring the correct type and dosing of cells, time, and method of
delivery and identify correct mechanism of functional improvement. An interdisciplinary eﬀort at the scientiﬁc, clinical, and the
governmentfrontwillbringsuccessfulrealizationofthistherapyforhealingtheheartandmayconvertwhatseemsnowaPandora’s
Box into a Pot of Gold.
1.ClinicalNeed
Myocardial infarction (MI) remains a major cause of mor-
bidity and mortality. Rapid reperfusion of the occluded
coronaryarteries is ofgreatimportance insalvaging ischemic
myocardium and limiting the size of infarct. This reduces
early complications and improves survival rates. Unfortu-
nately, myocardial necrosis starts rapidly before reperfusion
c a nb ea c h i e v e di nm o s to ft h ep a t i e n t s ,l e a v i n ga ni n f a r c t
zone that contains nonfunctional myocytes that are remod-
eled into the scar tissues surrounded by region of ischemia.
Contemporary reperfusion strategies using percutaneous
interventions aided with pharmacotherapy and mechanical
d e v i c e sh a v es h o w nt or e s o l v et h ei s c h e m i aw i t ho n l ym o d e s t
improvements in global Left Ventricular Function (LVF) as
evidenced by 2% to 4% increase in LV Ejection Fraction
(LVEF) at six months after an acute MI [1, 2]. This loss of
viable myocardium initiates a process of adverse ventricular
remodeling and a downward spiral leading to congestive
heart failure. This is followed by repeated hospitalization
and increased economic burden on the society with 50% of
the patients dying within ﬁve years of the diagnosis. Scar
tissue is incapable of performing the vital function of cardiac
muscle and suﬀers from decreased cardiac output. Revival of
the cardiac tissue in infarct zone can enhance the functional
activity of the heart. Thus, heart muscle salvage after heart
attack is the single important determinant factor for the
event-free long-term survival.
Considered as terminally diﬀerentiated organ, regener-
ating the myocardium was never thought of as an option
for heart muscle salvage. Stem cell-based therapy became
a realistic option to replace damaged heart muscles due
to series of experimental ﬁndings of myocyte turnover in
mammalian heart (Table 1). Evidence such as fraction of
cardiomyocytes may be able to reenter the cell cycle and
that limited regeneration can occur through recruitment
of resident and circulating stem cells were presented [3–
11]. But it was also realized that these endogenous repair
mechanisms are overwhelmed by the substantial damage
to the myocardium from the injury that it faces during
MI. However, the existence of these endogenous repair
mechanisms aswell astheconceptofadultstemcellplasticity2 Stem Cells International
Table 1: Evidence of myocardial regeneration.
Study Findings
Kajstura et al. 1998
[3]
14 ×106 myocytes in mitosis by confocal
microscopy.
Beltrami et al. 2001
[4]
4% myocytes in mitosis by labeling with
nuclei antigen Ki-67.
Hierlihy et al. 2002
[5]
Endogenous resident cardiac lineage
negative [L-] C-Kit + stem cells
diﬀerentiated into all three main
myocardial cell types; myocardial,
endothelial, and smooth muscle cell
types.
Laﬂamme et al.
2002 [6]
Quaini et al. 2002
[7]
Sex-mismatched cardiac
transplantations,homing of recipient’s
progenitor cells in the myocardium was
demonstrated. In the procedure Y
chromosome in situ hybridization was
used to track the male cells in the female
allografts coupled with immunostaining
to deﬁne the identity that these cells had
acquired.
Jackson et al. 2001
[8] and Bittira et
al. 2003 [9]
Marrow-derived progenitor cells circulate
and home to injured tissues similarly to
leukocytes, where they contribute to the
formation of new tissues.
suggested that cardiac repair may be achievedtherapeutically
in these clinical settings and gave a way for preclinical trials.
Subsequent promising reports of these same trials prompted
rapid initiation of human clinical trials. In the present paper,
we discuss the diﬀerent types of stem cells and their journey
inhealingtheheart,certain unresolvedissues anddiscuss key
points for the design of future stem cell therapy trials.
2.StemCells
Stemcellsareprimitive,undiﬀerentiated,undeﬁnedpluripo-
tent multilineage cells that retain the ability to renew them-
selves through mitotic cell division and can divide and create
ac e l lm o r ed i ﬀerentiated than itself. Every single cell in the
body originates from this type of cell. They are obtained not
only from embryo and fetus but also from various parts of
the adult body. Adult stem cells are deﬁned as undiﬀeren-
tiated progenitor cells from an individual after embryonic
development. Multiple tissues have been shown to contain
organ-speciﬁc progenitor cells. However, adult stem cells
have less potential to diﬀerentiate without assistance. Stem
cells are usually classiﬁed according to the following cri-
teria: origin, type of organ or tissue from which the cells
are derived, surface markers, and ﬁnal diﬀerentiation fate
(Table 2).
2.1. Embryonic Stem Cells (ESCs). ESCs are totipotent stem
cellsderivedfromtheinnermassoftheblastocyststagelatein
theﬁrstweekoffertilization.Theydiﬀerentiateintomulticel-
lular embryoid bodies containing diﬀerentiating cells from
a l lt h r e eg e r ml a y e r s ,e c t o d e r m ,m e s o d e r m ,a n de n d o d e r m ,
and are able to give rise to most somatic cell lineages [12–
14]. Since the mid-eighties, it has been shown that during
in vitro diﬀerentiation into cystic embryoid bodies, ESCs
diﬀerentiate into beating cardiac myocytes [12]a n da r e
electromechanically coupled to the host cardiac cells [15,
16]. ESC-derived cardiac myocytes most closely resemble
embryonic cardiac myocytesand express the complete reper-
toire of cardiac-restricted transcription factors including
GATA4, Nkx2.5, MEF2C, and Irx4 [17]. In several rodent
models it has been shown that, when transplanted into
infarcted myocardium,ESCs-derivedcardiomyocytesengraft
and improve cardiac function [18–21]. However, there are
certain limitations for their use. The ﬁrst is the likelihood
of teratoma formation at the implantation site. This can
be resolved by their diﬀerentiation prior to implantation
and thus yielding a pure cardiac myocyte population [22].
T h es e c o n di s s u ep e r t a i n st oi m m u n i t y .O n c et h o u g h t
to be uniquely immunoprivileged, increasing evidence has
demonstrated that ESCs express speciﬁc human leukocyte
antigen (HLA) subclasses [23]. This raises the worry of
graft rejection and might necessitate immunosuppression.
However, Steroiduse without concomitant stem cell implan-
tation has been known for some time to be harmful to
ischemic myocardium [24]. There is currently ongoing re-
search to help limit the immunogenicity of the cells for
allogeneic transplantation. Finally, the origin of ESCs has
raised considerable ethical concerns and led to heated
debates among scientists and the wider public. The recent
discovery that it is possible to generate ESC-like cells, called
inducible pluripotent stem (iPS) cells, by reprogramming
adult somatic cells with genes regulating ESC pluripotency
may resolve the ethical and immunogenic issues associated
with the use of ESCs [25–27].
2.2. Induced Pluripotent Stem (iPS) Cells. Induced pluripo-
tentstem(iPS)cellsarethestemcellsartiﬁcially derivedfrom
adultsomaticcellswhich havebeeninducedtoexpressagene
proﬁle characteristic of ESCs (Oct3/4, Sox2, KLF4, cMyc)
in response to genetic engineering [25, 28–30]. iPScells are
thought to be therapeutically equivalent to ESCs, in many
respects, suchastheexpressionofcertainembryonicmarkers
(SSEA-1) and proteins, chromatin methylation patterns,
doubling time, embryoid body formation, teratoma forma-
tion,viablechimeraformation,potency,anddiﬀerentiability.
Thesecellsaregeneticallyidenticaltothedonorcells[30,31].
In contrast to ESCs, the use of iPS does not generate ethical
controversies. Expansion of iPS in stem cell media can yield
as u ﬃcient number of cells that can subsequently be used for
studies on cardiac diﬀerentiation. But the full extent of their
potential and possible toxicity is still being assessed [28, 32].
2.3. Cardiac Stem Cells (CSCs). Several groups of investiga-
torsreportedthatthepostnatal heartincludesniches ofCSCs
and/or cardiac progenitors with the capacity to replicate
and diﬀerentiate into cardiac myocytes [18, 19, 33–39].
These cell populations included side population (SP) cells
(Hoechst 33342 and Rhodamine 123 dye negative) [5, 40],
cell expressing the stem cell factor c-Kit (CD117) [41], cellStem Cells International 3
Table 2: Major cell types with potentials for cardiac cell therapy.
Type Markers Advantages Disadvantages
Embryonic stem cells (ESCs)
Blastocysts (inner cell
mass)
— Totipotent and highly expandable
Immunosuppressionrequired, ethical
debate, lack of availability, and tumour
potential
IPS (induced pluripotent
cell)
Fibroblast (by
reprogramming adult
somatic cells with genes
regulating ESC
pluripotency)
—
Pluripotent indistinguishable from
ESCs at the epigenetic and
functional levels. Embryonic stem
cell like autologous adult cells for
cell therapy
Tumourigenesis
Adult/Fetal cardiomyocytes Isl+,L i n − c-kit+ Sca-1+
cardiosphere cells, SP cells
Multipotent
Cardiomyocyte phenotype
Electro-physiologically compatible
Immunosuppressionrequired, ethical
debate, short survival, and limited
supply
Skeletal myoblasts satellite
cells CD56+
Autologous transplantation,lack of
immunogenicity and high yield and
fatigue resistant, slow twitch ﬁbers
Electrophysiologically uncompatible,
lack of gap junction, arrhythmogenic
Hematopoietic stem cells
Bone marrow/peripheral
blood
CD34+,C D 4 5 +, CD133+
Multipotent, lack of
immunogenicity and autologous
transplantation,diﬀerent lineage of
cells
Quantum of cell population not
adequate
Mesenchymal Stem Cells
Bone marrow
Stromal/muscle,skin, and
adipose tissue
Adhesion molecules
(ALCAM/CD44)
Antigens
(SH2/SH3/SH4/STRO-1)
Allogenic/autologous
transplantation,lack of
immunogenicity (lack MHCII and
B7 expression), pluripotent and
cryopreservable for future use
Requires expansion
Endothelial progenitor cells
Bone marrow/peripheral
blood
CD133+
Autologous transplantation,
monopotent, lack of
immunogenicity
Need for expansion because of limited
supply
expressingthestemcellantigen1(Sca-1+)[42]cardiosphere-
derived cells [43] and expressing the protein Islet-1 detected
in the neonatal hearts. These cells are approximately 1/10th
the size ofadult cardiac myocytes. When isolated by repeated
panning or FACS sorting, 7–10% of these cells expressed
the early cardiac-restricted markers GATA4, Nkx2.5, and
MEF2 [39, 41, 44]. Expression of these markers does not
deﬁnitively mark a cell as cardiac in origin but does support
thisconclusion.Sincetheyarecardiacinorigin,perhaps such
cellsmightprovideamechanically andelectrophysiologically
compatiblesourceofcellsfortransplantation. These cellscan
be harvested from cardiac biopsies. They were demonstrated
to give rise to cardiomyocytes, endothelial cells (ECs), and
smooth muscle cells (SMCs) in preclinical and some animal
experiments with improved LV functions. SP cells [45–47],
c-kit cells [48–50], and cardiosphere cells [43, 51–54]w e r e
demonstrated to give rise to cardiomyocytes, ECs, and SMCs
in preclinical and some animal experiments with improved
LVF, while Sca-1+ CD31− cells were shown to diﬀerentiate
into cardiomyocytes and ECs in culture as well as in mice
after MI and improved cardiac function by promoting new
blood vessel formation [55]. CSCs isolated and cloned from
the heart ventricles of rat subjects have been shown to be
eﬀective in the treatment of myocardial ischemia, therefore
making the heart a viable source of stem cells for myocardial
repair [48].
Cardiac stem cells (as well as stem cells from other
tissues) appear to reside in specialized niches, which support
the growth and maintenance of the stem cell pool [56, 57].
Putative niches have been localized throughout the myo-
cardium, concentrated in deep tissue at the atria and apex
[41, 58]. Recent evidence has also shown that there is a
marked increaseinthenumber andmigrationofsuchcellsto
the injury areas following an ischemic insult [42]. Although
the diﬀerent cardiac stem cell pools are small relative to
the mature resident cardiomyocytes, they are believed to
be the source of new cells in normal organ homeostasis
as well as in stressed myocardium [59]. At present, it is
unclear if the various cardiac stem cells are distinct types
or whether they represent diﬀerent stages of a single cell
lineage. Furthermore, it appears that the cardiac stem cell
pool diminishes with ageing, possibly contributing to the
lack of eﬃcacy of regeneration in elderly individuals [59].
2.4. Skeletal Myoblasts. Often called “Satellite Cells” which
are found beneath the basal membrane of muscle ﬁbres lie
dormant till stimulated to proliferate by muscle injury or
disease [60]. These cells were the ﬁrst to enter the clinical
arena after completion of a decade of experimental testing
resultinginat least 40studies.Myoblastscanbeisolated from
skeletal muscle biopsies and expanded in vitro. These studies4 Stem Cells International
consistently showed diﬀerentiation of implanted myoblasts
intomultinucleatedmyotubes(notcardiomyocytes)with the
lack of connexin activity and absence of electromechanical
coupling with the host cardiomyocytes. Despite these appar-
ent short comings, a deﬁnite improvement in regional and
global LVF was demonstrated. These data along with the
clinically appealing characteristics of skeletal myoblasts (a
high in vitro scalability of the initial biopsy, an advance stage
of diﬀerentiation virtually eliminating tumorigenicity, and
a high resistance to ischemia) paved the way for the initial
human trials which started in June 2000 [61, 62]. Nonethe-
less, it would appear that enthusiasm for this approach is
waning. However, considerationsformodiﬁed orpreselected
productshavebeenformulated,anda“secondgeneration”of
skeletal myoblasts modiﬁed by cell enhancement techniques
have been hypothesized [63, 64].
2.5.BoneMarrowStemCells(BMSCs). Thebonemarrow ex-
empliﬁes a typical adult stem cell source containing diﬀerent
cell populations that have the potential to migrate and trans-
differentiate into cells of diverse phenotypes. Unfractionated
bone marrow cells contain diﬀerent stem and progenitors
cell populations including Haemopoietic StemCells (HSCs),
EndothelialProgenitorCells (EPCs),and Mesenchymal Stem
Cells (MSCs). Apart from these there are Multipotent Adult
Progenitors Cells (MAPCs) also derived from bone marrow
stromal cells. They have the ability to diﬀerentiate in vitro
in cells of three germ layers and diﬀerentiate into cardiac,
endothelial, and smooth muscle cell phenotypes.
2.6. Hematopoietic Stem Cells (HSCs). HSCs can be isolated
from bone marrow cells through selective sorting for a
particular set of surface antigen (Lineage negative [Lin−]c -
kit+,S c a - 1 +,C D 3 4 lo,a n dC D 3 8 hi)[ 65, 66] and represent the
prototypic adult stem cell population. They were shown to
diﬀerentiate into cardiomyocytes in culture, making them of
particular interest in thetreatment of cardiac disease because
they represent a well-characterized and ample source of
progenitor cells [67–70]. In vivo demonstration of the same
was given by Orlic et al. [71] by direct injection of Lin− c-
kit+ cellsintotheinfarct region.Numberoflandmark studies
followed then which showed signiﬁcant improvement in
cardiac function when these bone marrow-derived cells were
implanted directly ormobilized from endogenousreservoirs.
Some actually demonstrated regeneration of contracting
cardiomyocytes and improved ventricular function [72–74],
while others found beneﬁcial eﬀect independent of tissue
regeneration [75–77]. Nevertheless, the improvements seen
in ventricular function prompted a number of clinical trials
using autologous BMSCs to treat heart failure patients or
patients who had suﬀered an MI.
2.7. Mesenchymal Stem Cells (MSCs). MSCs represent a rare
population of cells with absence of HSC markers CD34
and CD133. They are about 0.01% of the mononuclear cell
fraction of the bone marrow and are also present in adipose
tissue.TheyarelessimmunogenicduetolackofMHC-IIand
B-7costimulatorymoleculeexpressiontherebypreventingT-
cell responses. They can diﬀerentiate into osteoblasts, chon-
drocytes, and adipocytes[78, 79]. DiﬀerentiationofMSCsto
cardiomyocytes-likecellswasobservedunderspeciﬁc culture
conditions wherein MSCs were induced to transdiﬀerentiate
into cardiomyocyte by 5-azacytidine, a DNA methylation
agent [80]. Animal studies have also shown that MSCs have
potential for site-speciﬁc diﬀerentiation into heart muscle
cells, vascular-like structures, as well as gap junction protein
[80–90]. These results suggest that MSCs act by regenerating
functionally eﬀective, integrated cardiomyocytes and possi-
bly new blood vessels. MSCs also have been injected into
infarcted myocardium via a catheter-based approach in pigs,
resulting in regeneration of myocardium, reduced infarct
size, and improved regional and global cardiac contractile
function. Importantly, the latter study used allogenic MSCs,
which did not produce evidence of rejection [89]. Because
MSCs clones can be expanded in vitro and reportedly have
a low immunogenicity, they might be used in an allogenic
setting in the future as cost-eﬀective“oﬀ-the-shelf” allogenic
cell product [91].
MSCs were derived from adipose tissue; adipose tissue-
derived stem cells (ASCs) were ﬁrst identiﬁed by Zuk et al.
[92] as a source of adult MSCs. After lineage-speciﬁc stimu-
lation, ASCs show multiple lineage diﬀerentiation potential.
They can diﬀerentiate into adipogenic, chondrogenic, myo-
genic, cardiomyogenic, osteogenic, endothelial, and neu-
rogenic lineages [93, 94] .A d i p o s et i s s u ei sa na b u n d a n t
expandable and easily accessible source of MSCs also eval-
uated for their therapeutic potential in regenerating heart
in animal model after MI [95]. In culture ASCs express cell
surface markers similar to those expressed by bone marrow
MSCs including CD117 (stem cell factor R), CD29 (beta
integrin), CD105 (multilineage diﬀerentiation markers),
CD54 (intercellular adhesion molecule-1 (ICAM-1), and
CD44 [78, 96].
2.8. Endothelial Progenitor Cells (EPCs). Cells with phe-
notypic and functional characteristics similar to the fetal
angioblast also are present in adult human bone marrow
[11]. Endothelial progenitor cells (EPCs) represent a subset
ofHSCsthat are able toacquire an endothelialphenotype.In
vitro [97–100] EPCs express the HSC markers CD34 and the
endothelial marker Flk-1 (vascular endothelial growth factor
receptor-2 (VEGFR-2)) [99]. EPC can be isolated directly
from the bone marrow or from the peripheral circulation
and expanded in vitro. Preclinical trials indicated that EPCs
contribute to 1–25% of vessel formation after ischemic
injury for several diseases [101]. They promote neovascu-
larization by secreting proangiogenic growth factors and
stimulate reendothelialization thereby contribute to vascular
h o m e o s t a s i sa n dp e r h a p sm y o g e n e s i s[ 102]. In the animal
experiments injection of EPCs into infarcted myocardium
improvedLVFandinhibitedﬁbrosis[11,103,104].Although
there was no change in the noninfarcted regions of the
heart,therewasasigniﬁcantreductionincollagendeposition
and apoptosis of cardiomyocytes and an improvement in
cardiac function on echocardiography [11]. It appearedStem Cells International 5
that neovascularization induced by these cells led to the
prevention of apoptosis and LV remodeling and led to some
degree of cardiomyocyte regeneration [105].
The cell surface antigen CD133+ is expressed on early
HSCs and EPCs and less than 1% of nucleated BMSCs, and,
because these cells cannot be expanded ex vivo, only limited
numbers of CD133+ cells can be obtained for therapeutic
purposes [106].
2.9. Fetal and Umbilical Cord Blood Cells (UCBCs). Because
oftheir prenatal origin, fetal and UCBCsmay possess greater
plasticity than adult cells. Human umbilical cord blood
contains a number of progenitor cell populations, including
HSCs and MSCs, in addition to a population of unrestricted
somatic stem cells, which have been shown to have prolifera-
tive potential [37, 107]. However, animal studies have shown
conﬂicting results with regard to improvements in LVF.
Ma et al. [108] injected human mononuclear UCBCs, a
small fraction (≈1%) of which were CD34+, intravenously
1 day after MI in NOD/scid mice. The cells homed to the
infarcted hearts, reduced infarct size, and enhanced neovas-
cularization with capillary endothelial cells of both human
and mouse origin. Interestingly, they found no evidence of
myocytes of human origin, arguing against cardiomyogenic
diﬀerentiation. In a rat model of MI [109] UCBCs CD34+
improved cardiac function when injected into the peri-
infarct rim immediately after MI compared with control
animals that receivedinjectionofmedium. Apart fromthese,
K¨ ogler and colleagues [110] have described a population of
cells from human UCBCs called unrestricted somatic stem
cells. These cells which are ﬁbroblast like in appearance and
adhere to culture dishes are negative for c-kit, CD34, and
CD45 and are capable of diﬀerentiating, both in vitro and
i nv i v o ,i n t oav a r i e t yo ft i s s u e s ,i n c l u d i n gc a r d i o m y o c y t e s .
These stem cells [111], when delivered by direct injection at
thoracotomy in immunosuppressed pigs after MI, improved
perfusion and wall motion, reduced infarct scar size, and
enhanced global cardiac function.
3.HumanClinicalTrials
As already mentioned in the beginning, modern reperfusion
strategies and advances in pharmacological management
that resolve the ischemia but not the infarct zone have
resulted in an increasing proportion of AMI survivors at
heightened risk of developing LV remodeling and heart
failure. None ofour current therapiesaddress the underlying
cause of the remodeling process, that is, the damage of
cardiomyocytes and the vasculature in the infarcted area.
BMSCs gained attentionas early as in the year 1968, with
the ﬁrst report of their clinical use for restoring the blood
and the immune system in children with congenital immu-
nodeﬁciencies [112]. However, host HSCs, used for blood
borne malignancies replace the donor HSCs and they do
not have to diﬀerentiate into another cell type. Therefore,
the revolutionary paper of Orlic et al. [71]w i t hav e r y
provocative ﬁnding which suggested that directly injecting
HSCs resulted in extensive myocardial regeneration and
Table 3: Animal experiments demonstrating myocardial genera-
tion with BMSCs.
Study Findings
Tomita et al. 1999
[90]
Transplantation of autologous bone
marrow cells to stimulate angiogenesis in
the recipient ischemic myocardium.
Functional improvement was observed
only in recipients of the mesenchymal stem
cells that had been treated with
5-azacytidine.
Orlic et al. 2001
[71]
Haematopoietic stem cells injected were
demonstrated to occupy the infarcted
region and resulted in extensive
myocardial regeneration.
Jacksonet al. 2001
[8]
The engrafted SP cells (CD34(−)/low,
c-Kit(+), Sca-1(+)) or their progeny
migrated into ischemic cardiac muscle and
blood vessels, diﬀerentiated to
cardiomyocytes and endothelial cells, and
contributed to the formationof functional
tissue.
Kocher et al. 2001
[11]
Systemic infusions of human bone
marrow-derived endothelial cell precursors
were able to intercept the remodeling
process of the left ventricle. The observed
neovascularization prevented apoptosis of
hypertrophied myocytes reducing collagen
deposition and subsequent scar formation.
Posttransplantation ventricle function
improved as well.
Orlic et al. 2001
[72]
That mobilizationof animal’s own bone
marrow with G-CSF before and after
myocardial infarction in mice resulted in
growth of new cardiomyocytes in the
infarct zone, improved ventricular
function, and substantially decreased
mortality by 68%.
subsequent various similar reports of animal experiments
(Table 3) gave a hope of using stem cells as tool in the hands
of mankind for regenerating myocardium [8, 11, 71, 72, 90].
Although their ﬁndings were subsequently challenged by
Balsam et al. [75], Murry and colleagues [76], and Chien
[113], the journey of stem cells as therapy in regenerating
the human myocardium had already begun with yet another
path breaking clinical study by Strauer et al. (2002) who
reported not only improved LVF in human trial but also
safety and eﬃcacy of infusing bone marrow mononuclear
fraction (BMMNCs) through intracoronary route although
in a very small study population [114].
Since then, there have been many published studies
[115]w i t hd i ﬀerent types of cells including composite of
BMMNCs, EPCs, MSCs, adipose cells, and cord blood cells.
The evidence that precursors of both cardiomyocytes and
endothelialcellsexist within themononuclearcellfraction of
a d u l tb o n em a r r o wf o r m st h eb a s i sf o rt h eu s eo fB M M N C s
in most of the clinical trials to date. After bone marrow
aspiration from large bones, most commonly the iliac crest
then mixed with heparin; the mononuclear cell fraction is6 Stem Cells International
obtainedbydensitygradientcentrifugationorsedimentation
protocol.The mononuclear fraction isinjected into the heart
without further ex vivo expansion. In addition, there has
been great variability in the number of cells transplanted (1–
400million), and the route of administration has included
intracoronary (by using the stop-ﬂow balloon catheter
approach), intravenous, epicardial, and intramural methods
[116].Theresultsofclinicaltrialspublishedtodateaiming at
progenitorcell-based myocardial repairin patientswith AMI
are summarized in Table 4(a).
O n ei m p o r t a n tp o i n tt h a th a st ob ek e p ti nm i n d
regarding the human trials is that the clinical studies diﬀered
significantly from the animal studies: (1) in the animals the
infarct-related artery was never reperfused, but cells were
directly injected into myocardium in the AMI condition,
(2) the majority of these trials utilized relatively unpuriﬁed
populations of BMMNCs which represent less than 0.1%
of stem cells, and none of these trials utilized the Lin−c-
kit+ cells described in animal experiments, and (3) most
importantly,theinfarctionwascreatedinanimalbycoronary
ligation and was not thrombus related.
The initial pilot studies by Strauer et al. [114], the
TOPCARE-AMI [117, 118], the BOOST-trial [119], and the
study performed by Fernandez-Aviles [120]a sw e l lo u r s
[121] reported nearly identical results—an improvement in
global LVEF by an absolute 6 to 9% and reduced LV end-
systolic volume (LVESV) at 6 months after cell transplanta-
tion. Overall, the published studies demonstrated that the
intracoronary infusion of autologous BMSCs is safe and
feasible in patients with AMI and on top of the beneﬁts asso-
ciated with established interventional and medical strategies
to promote functional recovery after AMI. Further improve-
ment of LVEF was mostly due to the improved regional
wall motion in the infarct border zone. However, there
are contradictory reports as well. Janssens and colleagues
[122] did not ﬁnd any improvement in their primary end
point after intracoronary transfer of BMMNCs, However,
they demonstrated a signiﬁcant reduction in scar size and
an improvement in regional function, but there was no
improvement in LVEF (P = .36). Their patient population
diﬀered from the BOOST trial in that they were reperfused
earlier and may therefore have gained only a small beneﬁt
from cell therapy because they derived maximal beneﬁt from
earlier reperfusion. The beneﬁcial eﬀects observed in most
of the pilot phase I/II studies were conﬁrmed in the so
far largest double-blind, randomized, multicenter REPAIR-
AMI trial [123] which demonstrated not only improved
LVF but also showed a reduction in the combined clinical
endpoint of death, MI, or revascularization in the BMSCs-
treatedpatientscomparedwith placeboafter1yearfollowup.
Patients with a lower baseline EF (≤48.9%) showed a
signiﬁcant3-foldhigherrecoveryinglobalLVEFaswell ason
clinical end points indicating that patients with more severe
MI proﬁt most from BMSCs therapy. Only one larger study,
the ASTAMI trial [124], did not show any beneﬁt on LVF
parameters. The reason for thefailure isconsidered tobe due
to their diﬀerent cell isolation and storage protocol, which
signiﬁcantly aﬀected the functional capacity of the cells. So
far, no trial has demonstrated a signiﬁcant eﬀect of BMSCs
transfer on LV end-diastolic volumes (LVEDV), suggesting
that unselected BMSCs may have a limited impact on LV
remodeling after AMI. Again, larger studies are required
to settle this issue. Followup data from the BOOST trial
[125]a sw e l la so u r s[ 126] show that the improvement of
LVEF is maintained after 18 and 24 months, respectively,
indicating that BMSCs transfer prevents progression of
diastolic dysfunction after AMI.
ThetherapeuticeﬀectsofMSCtransplantationafterAMI
have been investigated in two clinical trials. Chen et al.
[127] infused autologous MSCs by intracoronary route and
demonstrated no arrhythmias or other side eﬀects. After six
months of MSC transfer, regional wall motion and global
LVEF were improved, and LVEDV was decreased compared
witharandomizedcontrolgroupthathadreceivedanintrac-
oronary infusion of saline [127]. Unfortunately, it was not
reported whether intracoronary MSC delivery promoted
ischemic damage to the myocardium, a complication that
had occurred after intracoronary MSC infusions in dogs
[128]. Another study by Hare et al. [129] also demonstrated
that intravenous allogenic MSCs were safe in patients after
AMI with increased LVEF and reverse remodeling. Currently,
several studies have been undertaken for allogenic MSCs in
clinicaltrialsformyocardialregenerationintheUnitedStates
under the sponsorship of Osiris Therapeutics. Such an oﬀ-
the-shelf strategy for cell therapy would potentially make
the procedural logistics easier. Taken together, these studies
suggested that BMSCs or their selected cell populations are
safe and may improve cardiac function by a substantial
and clinically meaningful degree following MI. An extensive
meta-analysis by Abdel-Latif et al. [130] on eighteen eligible
studies (N = 999 patients) involving adult BMSCs such as
BMNNC, MSCs, and EPCs measuring the same outcomes
demonstrated that, as compared to controls, bone marrow
transplantation improved LVEF (pooled diﬀerence of3.66%;
95% conﬁdence interval (CI), 1.93% to 5.4%, P<. 001),
reduced infarct scar size (−5.49%; 95% CI: −9.1% to
−1.8%; P = .003), and reduced LVESV (−4.8%mL; 95%
CI: −8.2 to −1.41mL; P = .006). The available evidence
suggests that BMC transplantation is associated with modest
improvements in physiologic and anatomic parameters in
patients with both acute MI and chronic IHD, above and
beyond conventional therapy. This further suggests carrying
out multicentric randomized large trials targeted to address
the impact of intracoronary cell therapy on important
outcomes and long-term event-free survival as compared to
the conventional therapy.
Studieslikethose by Werneret al.[131]ha v eals opr ovid-
ed evidence of increased survival following AMI in patients
with greater number of circulating EPCs. This and positive
results of preclinical trials led to human trials to assess safety
and feasibility of EPCs [132–134]. The results of these trials
showedtrendtowardsimprovementofLVFinbothacuteand
chronic ischemia, without adverse eﬀects [133, 135–137].
The ability of injured myocardium to recruit extra-
cardiac stem cells following injury is critical in myocardial
repair and regeneration. Little is known with regard to the
regulatory mechanisms that control the homing and holding
of stem cells to injured tissues. The precise time course,Stem Cells International 7
Table 4
(a) Summary of major cell-based clinical trials
Study Method of
delivery
Patients
treated/control Placebo/control
Cell type
cell/number or
dose
Time of cell
delivery (days
after MI)
Results
Strauer et al., 2002
[114]( G e r m a n y ) IC 20/10 Case controlled BM-MNC
9–28 × 106 7
Improved
contractility and
reduced infarct size at
6m o n t h s
TOPCARE-AMI,
Assmus et al. 2002
[117], Sch¨ achinger
2004 [118]
(Germany)
IC 30/29
Control
Nonrandomized
open-labeled
BM-MNC
2.4 × 108
CPC 1.3 × 107
3t o7
Improved LVFE and
reduced infract size at
4–12 months
BOOST,
Wollert et al. 2004
[119],
IC 30/30 Control BM-MNC
24 × 109 6
Improved EF at 6
months, increased
regional contractility,
Meyer et al. 2006 [125]
(Germany)
no diﬀerence at 18
months
REPAIR-AMI,
Sch¨ achinger et al.
2006 [123]( G e r m a n y )
IC 102/102 Placebo BM-MNC
2.4 × 108 4
Improved EF and
reduced infarct size at
4m o n t h s
Fernandez et al. 2004
[120] IC 20/13 Control BM-MNC
11–90 × 106 10–15
Signiﬁcantfunctional
improvement and
reduced infarct size
Janssenset al., 2005
[122]( B e l g i u m ) IC 33/34 Placebo BM-MNC
3.0 × 108 cells 1
Decrease scar size but
no improvement in
LVEF at 4 months
ASTAMI, lunde et al.
2006 [124]( N o r w a y ) IC 50/50
Control
Randomized + placebo
controlled
BM-MNC
8.7 × 107 5t o8 No diﬀerence at 6
months
Shah et al. 2007
[121, 126]( I n d i a ) IC 20/10
Control
Open-label
nonrandomized
BM-MNC
13.4 × 107 6t o8
Improved LV
function at 6 months
and sustained at 24
months
Chen et al. 2004 [127]
(China) IC 34/35 Placebo
Controlled
MCSs
48–68 × 1010 18
Inc LVEF, Inc regional
contractility, increase
viability of infarct
zone/wall after 3 and
6m o n t h s
Hare et al. 2009 [129]
(USA) IV 39/21 Double-blind placebo
controlled
MSCs 0.5, 1.6,
5millioncells/kg
1, 2, 3, 6 months
followup
Improved LVEF and
reverse modeling
IC: intracoronary, IV: intravenous, BM-MNC: unfractionatedbone marrow mononuclearcells, CPC: Circulatingprogenitor cells, MSCs:mesenchymalstem
cells.
(b) Summary of major cell-based clinical trials
Study Method of
delivery
Patients
treated/controlled Placebo/control
Cell type, cell
number, or
dose
Time of cell
delivery (days
after MI)
Results
Ince et al. 2005 [152]
First Line-AMI
(Germany)
Mobilization
of G-CSF 15/15 Randomized +
controlled
BM-MNC
CD34+ 1–6
After 4 and 12 month
followup improved
LVEF and systolic wall
thickness
Ripa et al. 2006 [153],
STEMMI (Denmark)
Mobilization
of G-CSF 39/39
Randomized +
placebo
controlled
BM-MNC
CD34+ 1–6
After 6 month
followup systolic wall
thickness ↑ viability of
infarct zone/wall8 Stem Cells International
(b) Continued.
Study Method of
delivery
Patients
treated/controlled Placebo/control
Cell type, cell
number, or
dose
Time of cell
delivery (days
after MI)
Results
Zohlnh¨ ofer et al. 2006
[154], REVIVAL
(Germany)
Mobilization
of G-CSF 56/58
Randomized +
placebo
controlled
BM-MNC
CD34+ 1–6 After 4 and 6 month
followup No eﬀects
Engelman et al. 2006
[155],
G-CSF-STEMI
(Germany)
Mobilization
of G-CSF 22/22
Randomized +
placebo
controlled
BM-MNC
CD34+ 1–5
After 4 and 6 month
followup
No eﬀects
kinetics, and factors stimulating bone marrow mobilization
remain the subject of intense investigation. Several crucial
factors have been shown to promote the mobilization of
BMSCs into peripheral circulation, including granulocyte
colony-stimulatingfactor(G-CSF),granulocyte/macrophage
colony-stimulating factor (GM-CSF), stem cell factor (SCF),
vascular endothelial growth factor (VEGF), hepatocyte
growthfactor(HGF),and erythropoietin(EPO)[138].Myo-
cardial ischemia is known to induce several “mobilizing cy-
tokines”, including, but not limited to, G-CSF [139–141],
SCF [139–141], VEGF [141–145], stromal derived factor
(SDF-1) [139, 141, 145, 146], and EPO [147, 148]. These
cytokines may be responsible for the observed homing
of BMSCs following MI. Mobilization of BMSCs through
cytokine stimulants increases their concentration in the
peripheral circulation substantially. In addition to well-
recognized HSCs mobilizing agents such as G-CSF and
SCF, VEGF, and EPO and statins have been shown to
promote EPC recruitment [148–151]. Several clinical trials
(Table 4(b)) were carried out with mobilization of BMSCs
with G-CSF [152–155]. Abdel-Latif et al. [156] also carried
out meta-analysis of clinical trials wherein BMSCs were
mobilized with G-CSF. The analysis revealed that G-CSF
therapy in unselected patients with AMI appeared safe but
did not provide beneﬁt. Subgroup analyses suggest that G-
CSF therapy may be salutary in AMI patients with severe
LV dysfunction and when started early. Larger randomized
studies may be conducted to evaluate the potential beneﬁts
ofearly G-CSF therapyin AMIpatients with LVdysfunction.
3.1. Safety and Long-Term Beneﬁt of Cell Therapy. Stem cell
potency is a double-aged sword, and therefore, although the
initial experimental studies conﬁrmed that the infusion of
BMSCs do not cause major side eﬀects, several potential
issues were raised such as electrical stability, increased res-
tenosis, or progression of atherosclerotic disease. However,
none of the clinical studies with BMSCs so far have reported
an increased incidence of arrhythmias (as have been seen in
some of the myoblast trials), bleeding complications, addi-
tional ischemic injury, or promoted inﬂammatory reaction
as no further increase in CRP, and troponin was observed
including in our study.
Restenosis, which was considered as potential side eﬀect
by progenitor cell-mediated plaque angiogenesis or plaque
inﬂammation, was only increased using CD133+ cells [157,
158]. This is surprising, because the isolation of selected
progenitor cells excluding contaminating proinﬂammatory
cellswouldhavebeen assumed toreduceratherthan increase
the risk of restenosis and atherosclerotic disease progression.
Because CD133+ cells were isolated by using a mouse an-
tibody, one may speculate that the remaining antibody
might have elicited a local proinﬂammatory reaction despite
the failure to detect systemic antimouse antibodies in the
patients. All other studies did not observe an augmented
risk for restenosis [159]; if anything, there was a decreased
necessity for revascularization procedures in the REPAIR-
AMI trial [123].
Intramyocardial calciﬁcation which was reported to
occur in murine models of MI after direct injection of un-
puriﬁed BMSCs or MSCs [160, 161]w a sn o tr e p o r t e di n
the various clinical trials as reported by MRI imaging. This
may be explained by the enrichment of mononuclear cells by
density gradient centrifugation used in the majority of the
clinical studies.
It had been discussed that the proangiogenic capacity
particularly of EPCs might relate to an increased tumor
vascularization. However, during followup of the available
studies,noincreased incidenceofcancerwasseen inBMSCs-
treated patient. Most oftheclinicaltrials did excludepatients
withknowntumors.Itisunclearwhetherasingleapplication
of EPCs is suﬃcient to promote tumor growth. However,
because of the low incidence of such events, this needs to be
carefully monitored in the future.
An important issue is whether the improvement seen
during the initial 6 months after cell therapy is maintained
for a prolonged time. Careful evaluation of the 18 months
followup data of the BOOST trial indicates that the EF of
the cell therapy group is maintained from 6 to 18 months
followup [125]; however, the diﬀerence between the cell
therapy and the control group was no longer statistically
signiﬁcant. The small number of patients (30 per group)
may preclude detecting a statistical diﬀerence between the 2
groups. The long-term 5-year followup MRI-derived data of
the TOPCARE-AMItrial showed that theEF was maintained
and even further augmented in the treated patients, in
parallel with a sustained reduction in NT-proBNP serum
levels suggesting a sustained beneﬁcial eﬀect on long-term
LV remodeling (S. Dimmeler and A. M. Zeiher, unpublished
data). In our study also the improvement seen at 6 months
in LVF was sustained at 24 months. However, longer-term
followup in larger-scale randomized trials will ﬁnally addressStem Cells International 9
this important question. Overall,the clinical data available at
present indicate that cell therapy with bone marrow-derived
cells is feasible and safe at least for the duration of followup
presently available (up to 5 years for the initial studies).
4.Mechanism of Myocardial Repair
One could see that, although the early phase of research
in cardiac repair aimed at histologic outcomes, the human
trial of last ﬁve years demonstrated improvement of heart’s
function as their clinical end point and have erroneously
reasoned that, because ventricular function was improved,
the heart was regenerated. This shift towards physiology
made mechanism less evident. There is still controversy as to
whether actual diﬀerentiation occurs versus large cell fusion
with resident myocytes. This is because on one hand the
myocyte deﬁcit in infarction-induced heart failure is on the
order of one billion cardiomyocytes and on the other hand
the documentation of LVF improvement within 72 hours is
farearlierthanwouldbeexpectedforcellregeneration ofany
meaningful extent [162].
The fact that after transplantation of hundreds of
millions of cells, less than 2% of the cells are actually still
presentin thetissuewithin 2weeksofimplant;theprevailing
concept of stem cell eﬃcacy has shifted toward the cytokine-
paracrine hypothesis [163]. It has also been proposed that
through paracrine mechanisms stem cells release angiogenic
ligands, protect cardiomyocytes from apoptotic cell death,
induce proliferation of endogenous cardiomyocytes, and
may recruit resident CSC (Figure 1). Indeed, various studies
showed that progenitor cells secrete survival factors such
as endothelial growth factor, stromal-derived factor (SDF-
1), angiopoietin 1, hepatocyte growth factor, insulin-like
growth factor 1, and periostin [77, 164–169], thymosin
b4 which promotes wound healing or the Wnt antagonist
secreted frizzled-related protein 2 (SFRP-2) which protects
cardiomyocytes from hypoxia-induced apoptosis [170–172]
and thus stimulate tissue recovery after ischemic injury and
minimize the infarct size [165, 167, 173–176]. Regardless of
the mechanisms, there appears to be general agreement that
stem cell therapy has the potential to improve perfusion and
contractile performance of the injured heart.
5.Issuesto Be Addressedin theFutureStudies
The ultimate aim of the cellular transplantation remains
to be the regeneration of lost heart muscle along with
the reversal of the remodeling process. It is possible that
the apparently variable results among diﬀerent trials are
secondary to diﬀerences in the protocols. Despite growing
clinical experience, use of these heterogeneous parameters
along with various clinical end points among human trials
have left us with fundamental questions regarding the use of
the ideal cell type; the number of cells needed to be delivered
for maximal eﬃcacy; optimal isolation, puriﬁcation, and
storage techniques; ideal route of delivery; ideal time of
administration after injury to improve the eﬃcacy of this
therapy as well as for this therapy to be includedunder treat-
mentguidelines.Thetrialsdiscussedabovewerenotpowered
to address the eﬀects on these hard clinical end points but
can give us some direction towards standardization of the
therapy on above parameters.
5.1. Which Cell Populations Should Be Delivered?
While the ideal cell type for stem cell therapies remains
to be determined to date, bone marrow-derived stem cells,
isolated from whole bone marrow aspirate, remain the most
commonly used cell type for human studies. Unfraction-
ated bone marrow cells gained advantage over above cells
due to many reasons. It has the feasibility of procuring,
no requirement of in vitro expansion and above all the
availability of mixed population of cells with characteristic
for diﬀerentiating into various populations of cells. And of
course it has no ethical issues. However, importantly MSCs
have also emerged as most promising cell population with
their inherent property of transdiﬀerentiating into cardiom-
yocytes and to be tolerated by the immune system giving us
the most convenient “oﬀ-the-shelf” reagent.
5.2. What Number of Cells Should Be Given?
Murry et al. [162] have pointed out that number of cells
administered reportedstudiesrangebyasmuchas6700-fold.
Myocardium contains approximately 20 million cardiomy-
ocytes per gm of tissue [177]. The average left ventricle ap-
proximately weighs 200g and therefore contains approxi-
mately 4 billion cardiomyocytes. To cause a heart failure,
an infarct needs to kill approximately 25% of the ventricle
(for comparison, infarcting 40% of the ventricle results
in acute cardiogenic shock) [178]. Therefore, the myocyte
deﬁcit in infarction-induced heart failure is in the order of
one billion cardiomyocytes. True cardiac regeneration would
therefore require restoring approximately one billion cardi-
omyocytes and ensuring their synchronous contraction via
electromechanical junctions with host myocardium.
5.3. When Dose Cells Should Be Transplanted?
In the ﬁrst 48 hours of AMI attack, debridement and
formation of a ﬁbrin-based provisional matrix predominates
before a healing phase ensues [179]. At the initial 3-4 days
after MI cell adhesion, molecule concentration which has
not yet declined may promote the transplanted cells into
inﬂammatory process than in the formation of functional
myocardium [180]. It is only by 7th day after MI that VEGF
concentration peaks and cell adhesion molecule concentra-
tion declines [181, 182]. By 2 weeks after scar formation,
the beneﬁts achieved due to cell transplantation are reduced.
Therefore, the ideal time point oftransplantation remains 7–
14 days [105]. This was very much evident in the REPAIR
AMI trial [123] wherein patients being treated up to 4 days
after the MI showed no beneﬁt, whereas later treatment
(day 4 to 8) provided an enhanced improvement of EF
during follow-up. This suggests that microenvironment after10 Stem Cells International
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Figure 1: Mechanism of action of stem cells for cardiac functional improvement.
AMI changes during the ﬁrst week after reperfusion, thereby
modulatingthehomingorthesubsequentfunctional activity
of the infused cells and cell homing might be best after a
few days rather than immediately after reperfusion. Further
studies are warranted to prospectively address this question
[183].
5.4. Cell Processing. Standardization of cell isolation proto-
cols which have a major impact on the functional activity
of bone marrow-derived progenitor cells is also a crucial
issue. The comparison of the cell processing of ASTAMI
and REPAIR trials highlighted a very crucial point that the
assessment of cell number and viability may not entirely
reﬂect the functional capacity of cells in vivo [184]. Addi-
tional functional testing appears to be mandatory to assure
propercellfunctionbeforeembarkingonclinicalcelltherapy
trials. The recovery of total cell number, colony-forming
units (CFU), the number of MSCs, and the capacity of
the isolated BMSCs to migrate in response to SDF-1 was
signiﬁcantly reducedwhen usingtheASTAMI[124]pr ot oc ol
of Lymphoprep, storage in NaCl plus plasma compared with
the REPAIR [123] protocol of Ficoll, and storage in X-vivo
10 medium plus serum. Comparison of the individual steps
identiﬁedtheuseofNaClandplasmaforcellstorageasmajor
factors for functional impairment of the BMSCs in ASTAMI
trail.
5.5. Speciﬁc Setup Required for Clinical Cell Therapy to Ensure
Quality Control and Safety. The application of BM-derived
cells to patients is a complicated process starting from the
operating theatre, then moving to the laboratory, and ﬁnally
returning to the operating theatre or cardiac catheterization
laboratory. Aseptic techniques are used throughout to con-
trol contamination. In today’s clinical practice such a process
must comply with good manufacturing practice (GMP) to
reduce risks to the eventual recipients. Accordingly, cell
therapy centers should be GMP accredited, wherein trained
personnel operates under speciﬁc facilities (air ﬁltration
systems, clean room, and cell culture laboratory facilities)
following the GMP standards. Similar setups for hematopoi-
etic stem cell therapy should be adopted in hospitals
worldwide. Cell processing may inadvertently expose human
cells with a variety of hazards and contaminations. The
major concern is zoonotic contamination, as animal-derived
materials (e.g., fetal calf or bovine serum) are commonly
used in cell cultures. This problem could be overcome by
using commercially available serum-free media (with growth
supplements). In the meantime, Autologous Human Serum
may beconsidered asa replacementtoanimal serum. Finally,
prior to the delivery in patients, cell supernatants must be
testedforinfectiousagentsatdiﬀerenttimepointsdependent
on the speciﬁc protocol [183].
5.6. Which Application Method Is the Most Eﬃcient?
The most commonly utilized method of stem cell delivery
is the transvascular approach. It is suited for the treatment of
recentlyinfarctedandreperfusedmyocardiumwhichdelivers
maximum cells to the site of injury. Cells are delivered
through the central lumen of an over-the-wire balloon
catheter during transient balloon inﬂations to maximize the
contact time of the cells with the microcirculation of the
infarct-related artery. This stop-ﬂow technique is relatively
easy to perform within less than an hour and enhances cell
retention within the infarcted area. Direct needle injection
of the stem cells into the infarcted regions of the heart that
requires an open-chest procedure may not be possible all the
time for human patients [106].
TheuseofIVtherapycouldbemoreeﬀectiveconsidering
that the cells have the advantage of reaching the tissue and
vessels surrounding the infarct region. When using direct
infusion, the cells primarily reach the area that they areStem Cells International 11
injected into, whereas IV administration is not necessarily
limited to the immediate infarcted region. It is possible
that the stem cells will also repair areas of the heart
damaged during any previous injury and not detected by
imaging, therefore preventing any future problems in that
region. Since IV administration is safer for use on humans
than catheterization, clinical trials utilizing IV therapy with
humans would be a critical step for the standardization of
stem cell treatment. Hare et al. [129] had used intravenous
approach to deliver the allogenic MSCs to the infarct region
with positive outcome.
5.7. Development of Safe and Eﬀective Cell Tracking Modal-
ities. Because the mechanism through which cell therapy
acts is still being characterized, clinical trials that establish
mechanistic correlates will be most helpful. For example,
studies using MRI in patients suggest that cell therapy might
alter the rate of infarct repair or inﬂuence the amount of scar
contraction [122]. Positron emission tomography studies
have demonstrated glucose uptake and enhanced myocardial
blood ﬂow in cell-engrafted regions [117, 119, 128, 185,
186] which provide important information regarding eﬀects
on tissue metabolism and perfusion. Another very useful
mechanistic end point for clinical trial is the ability to track
the cells after they are implanted, for instance, through use
of paramagnetic particles visible by MRI [187], positron
emitting isotopes [188], or molecular tracers [189]. Finally
tissue-based analyses should be included in clinical trial
design, either by evaluation of explanted hearts at the time
of the transplantation [190] or by autopsy of patients who
die following cell therapy [191].
The huge scope of the problem from the bench to the
bedside and back again led to the establishment of consortia.
The Cardiovascular Cell Therapy Research Network, which
comprises 5 institutions and is sponsored by the National
Heart,Lung,andBloodInstitute,will addressaspeciﬁc series
of questions over a 5-year period. Broadly speaking, the
major objectives are to develop phase 1 and 2 clinical trials
for cell delivery for left ventricular dysfunction (AMI and
chronic heart failure) while deﬁning parameters and models
for successful translation of newer cell types [192].
6.Cell-EnhancementStrategies
Apart from the standardized steps obtained from the clinical
trials to continue the research at bedside, there needs to
be done a lot at bench side to make this trial eﬀective
and more speciﬁc. Pretreatment of the targettissues enhance
active cell recruitment, survival, and retention; the potential
strategies include modiﬁcation of the target region by low-
energy shock waves or ultrasound-mediated destruction
of microtubules in the coronary circulation that increase
retention of EPCs, BMMNCs, and MNCs.
Many cytokine and paracrine factors that favorably aﬀect
angiogenesis,inﬂammation, cytoprotection,metabolicmod-
ulation, and apoptosis have been identiﬁed. Activation or
introduction of chemotactic factors such as SDF-1 or its
receptor CXCRF4, high-mobility group box-1 (HMGB-1),
β2 integrin, and endothelial nitric oxide synthase to attract
cells to the damaged area can be carried out. Another area of
interest relatestothedeclineinthenumber andfunctionality
of autologous stem cells in association with comorbid
conditions and whether such “sick” cells can be functionally
rejuvenated before transplant. Experimental studies of cell-
enhancement strategies have identiﬁed a number of novel
and intriguing options for improving survival, retention,
integration, and homing. These include through genetic
modiﬁcation of stem cells before transplant [193, 194], that
is, the transduction of cells with prosurvival genes (e.g.,
the protein kinase Akt, telomerase reverse transcriptase (the
active subunit of telomerase), vascular endothelial growth
factor, and integrin-linked kinase) and the pretreatment of
cells with small molecules (e.g., statins, P38 inhibitors, and
endothelial nitric oxide synthase (NOS3)), so as to activate
the Akt/NOS3pathway [195–197].
Finally, next directions of cardiac cell therapy include following
[197]:
(1) The study of the array of bioactive molecules that are
secreted by stem cells, which have been demonstrated to
induce neovascularization, modulate inﬂammation, ﬁbro-
genesis, cardiac metabolism, and contractility, increase car-
diomyocyte proliferation, and activate resident stem cells.
The exhaustive analysis of this “secretomes” of BMMNCs,
MSCs, or EPCs would lead to a better understating of the
mechanisms of action of the cells and to a hypothetical
protein-based therapy (oﬀ-the-shelf, noninvasive, systemic,
and repetitive administration); (2) the use of diﬀerent
sources of pluripotent stem cells, like ESCs, spermatogonial
stem cells, and oocytes. A new era has been initiated
with the possibility of reprogramming adult cells (skin
ﬁbroblasts) to a pluripotent state by retroviral transduction
[26, 198]. These iPSs show the characteristics of ESCs and
can diﬀerentiate to cardiomyocytes. New retroviral vectors
and even nonviral vectors have been developed to reduce the
risk of mutagenesis, and genetic modiﬁcation of cells with
suicide geneshave beenproposed to reduce the risk of tumor
formation; (3) the creation of bioartiﬁcial hearts after a
processofdecellularizationwithdetergents,abstentionofthe
underlying extracellular matrix (cardiac architecture), and
stem cell repopulation [199]. The “acellular” heart can then
be reseeded with CSCs or EPCs, showing contractile activity
in animal models. This new approach of tissue bioengineer-
ing has opened a fascinating era in cardiovascular medicine.
6.1. Strategies for Generating Cardiac Myocytes. Pretrans-
plantation conditioning/speciﬁcation of cells to the cardiac
phenotype has been studied
6.1.1. ESCs and iPS. The cardiac diﬀerentiation potential of
iPS was carried out by selecting the mesodermal marker Flk-
1( V E G F R - 2 )f r o md i ﬀerentiating iPS and then a further
coculture with OP9 cells. It resulted in the induction of
cardiac myocytes [200]. These myocytes have also been12 Stem Cells International
demonstrated to be functionally and structurally similar to
those derived from ESCs, but the yield was still low.
Pretransplantation conditioning/speciﬁcation of cells to
the cardiac phenotype has been widely explored in studies
with ESCs. The induction of spontaneous beating in vitro
of ESC cultured as embryoid bodies with the addition of
members of the transforming growth factor family proteins
(TGFβ1, BMPs) appears to be a common approach. Coordi-
nated beating areas in the cultures are then isolated, char-
acterized for the expression of cardiac genes, and used for
transplantation [15, 19, 201].
A noticeable work was performed by Kehat et al. [202],
where theelectrophysiology couplingofhuman ESC-derived
cardiac myocytes (ESC-CM) was completely dissected with
in vitro cocultures of these cells with rat postnatal cardiac
myocytes and in vivo after transplantation in animal models
of cardiac dysfunction.
Laﬂamme et al. [203] took a two-tiered approach to
ESC-based therapy of AMI by preconditioning the cells
initially toward cardiac lineage and then treating the cells
with a prosurvival cocktail 3. The directed diﬀerentiation of
hESCs by treatment with BMP4 and Activin increased the
yield of myocytes to 30%. The prosurvival cocktail markedly
increased cell engraftment and survival. This combination of
treatments greatly augmented remuscularization and cardiac
function.
6.1.2. Adult Stem Cells. Adult stem cells pretransplantation
speciﬁcation to the cardiac phenotype has received some
attention, although not in the clinical realm.
MSCs have been shown to express basal levels of major
cardiac proteins such as cardiac myosin, actinin, and others,
have capacity to readily occupy the infarcted tissue before
cardiacﬁbroblastdo,avoidingﬁbroticscar formation, aswell
as secrete survival factors that in turn maintain remaining
cardiac myocytes viability and induce endogenous cardiac
stem cells to diﬀerentiate and recover lost tissue/function.
However, cardiac diﬀerentiation of MSCs integrated into the
infarcted cardiac tissue, in terms of sarcomeric organization
and coordinated beating has not been reported to date. In
a recent publication pretreatment of MSCs with a com-
bination of growth factors, basic ﬁbroblast growth factor;
insulin growth factor-1, and bone morphogenic protein-2
(FGF2/IGF-1/BMP2, resp.) induced cardiac protein expres-
sion and antiapoptotic signals in adjacent cardiac myocytes
in vitro. This study detailed the importance of gap junction
proteins such as conexin-43, which has enhanced expression
in hearts transplanted with growth factor pretreated MSC
[204].
Enhanced expression of cardiac proteins such as Tropo-
nin-I and conexin-43 after 7 days of treatment with TGFβ1
was observed in immunogenic selected MSCs expressing
the oncogene c-kit also known as CD117. Li et al. demon-
strated that CD117+ cells transplanted into infarcted hearts
improved cardiac function determined by cardiac wall
thickness and shortening fraction [205].
7.Philosophicaland EthicalIssues
Because of the innovative nature of these treatments, dif-
ferences between animal and human physiology, limited
experience with these cells in humans, and the high hopes
of desperate patients for whom no alternative eﬀective
treatment currently exists, the focus should be on reducing
risks and providing rigorous evidence of eﬃcacy and safety
within the ethical guidelines. In general, the fundamental
regulatoryandethicalrequirementsthatareusedindrugand
other clinical trials apply equally to cell therapy [206, 207].
In addition, the use of embryonic material for research
will require formulation of additional safeguards by which
cells are manipulated and engineered, which in turn will
be inﬂuenced by attitudes of governmental administrations
[208]. The lack of precedent in this area of science mandates
a close interaction among regulators, scientists, clinicians,
and the public because the potential for misunderstanding
on all sides is considerable. Other issues include those
of ownership of cell lines, intellectual property, patents,
collection of blood in minors (i.e., umbilical cord blood
donations), the potential eﬀect of conﬂict of interest on
research study recruitment, and analysis of results [209–
211]. Because use of patient’s autologous stem cells does
not directly involve intellectual property, funding of stem
cell research by the biotechnology industry has been limited
to either cell isolation or delivery devices. Perhaps this
situation will change with the emergence of new stem
cell lines that are not autologous and the development of
unique processing capabilities, but these issues in turn have
raised concerns with regard to ownership, price control,
and the availability of cell lines. For the present, expensive
randomized controlled clinical trials are funded primarily by
nonindustrial sources, introducing a diﬃcult challenge for
the academic community of disease [208].
Some speciﬁc ethical recommendations have been given
for Randomized Clinical Trial (RCT) with stem cells [210].
They include the following.
(1) Phase I-II trials should enroll participants in late
stages of serious illness, such as persons with
advanced or refractory disease, butnot so ill thatthey
are at greatly increased risk for adverse events.
(2) Use a proper control group, in order to evaluate the
positive eﬀectsoftreatment and to ascribe culpability
to any MACE seen with cell therapy. Then stem cells
can be oﬀered to the control group at the conclusion
of the trial if the results show short-term beneﬁt
(cross-over).
(3) Use clinically meaningful endpoints.
(4) Coordinate scientiﬁc and ethical review, judging
the potential clinical beneﬁt of the treatment and
assessing the scientiﬁc justiﬁcation for the trial,
including proof-of-principle and preclinical data on
safety and dosage.
(5) Verify that participants clearly understand the fea-
tures of the trial. Since a comprehensive informed
consent form may not prevent misconceptions aboutStem Cells International 13
the trial, additional information should be given to
those patients with signiﬁcant misunderstandings.
Participants should appreciate that researchers may
not know whether or not the stem cell treatment will
be beneﬁcial, that animal studies might not predict
eﬀects of the cells in humans, and that unexpected
adverse events may occur.
(6) Ensure publicationof results, even negative ones. For
the interest of patients, researchers, and sponsors,
negative ﬁndings cannot be withheld from publica-
tion.
The Task Force of the European Society of Cardiology
on stem cells and repair of the heart was created in 2006
to investigate and regulate the role of progenitor/stem cell
therapy in the treatment of cardiovascular disease. It was
almost four years ago that this group of experts and opinion
leaders stated the type of studies needed [212]. On the other
hand, the Task Force stated that small uncontrolled trials
withBMMNCsshould beavoided,astheyareunlikelytoadd
anything new to the ﬁeld.
The points stated were the following:
(1) further large, double-blind, multicentric controlled
RCT for the use of autologous BMSCs in the treat-
ment of AMI. The patient population should be all
those presenting within 12 hours of AMI and treated
with immediate revascularization, be it primary
angioplasty or ﬁbrinolysis;
(2) double-blind, controlled RCT for the use of autol-
ogous BMSCs in the treatment of AMI in those
patients presenting late (>12 hours) or who fail to
respond to therapy (candidates for “rescue” angio-
plasty). Although these groups may represent a small
proportion of all patients with AMI, their prognosis
remains poor;
(3) double-blind, controlled RCT for the use of autol-
ogous BMSCs or SM in the treatment of ischemic
heart failure. At some stage, the role of autologous
stem/progenitor cells in the treatment of cardiomy-
opathies (in particular, dilated cardiomyopathy) will
need to be examined;
(4) a series of well-designed small studies to address
safety or mechanism to test speciﬁc hypotheses (i.e.,
studieswithlabeledcellsortoinvestigateparacrineor
autocrine mechanisms). Such hypotheses would have
arisen from basic science experiments;
(5) studies to conﬁrm the risk/beneﬁt ratio of the use of
cytokines alone (i.e., G-CSF) or in conjunction with
stem/progenitor cell therapy. This Task Force also
underlined the necessity for studieswith hard clinical
endpoints, MACE, subjective beneﬁt, and economic
gain;
(6) another key point is standardization, both in out-
come measures and in the processing of cells (better
achieved in specialized centers following Good Man-
ufacturing Procedure routines), in order to derive
meaningful comparisons.
8.Conclusion
The Orlic trial almost ten years ago that fueled excitement
of using stem cells for cardiac regeneration was itself under
criticism. However, often “Science Proﬁts from Mishaps.”
Many of the bigger discoveries and inventions have followed
such traumatic experiences. Had Andreas Gruentzig not
embarked on clinical applications after experimenting on
just 8 dogs, a new ﬁeld of interventional cardiology would
not have emerged. Therefore, the risk of exposing patients
to possible adverse outcome of any new treatment must be
weighed against the risk of depriving all patients of new
treatment to alleviate suﬀerings or prolong the life. The
argument that these trials should be delayed till mechanisms
are further understood will prevent large number of patients
from therapeutic approaches that may improve their clinical
outcome. There is a wealth of preclinical and early clinical
datashowingsafety,feasibility,andearlyeﬃcacyofadultcell-
based therapy. The apparent lack of immediate commercial
or industrial interest should not discourage the scientiﬁc
community from adopting a disciplined strategy in pursuing
this ﬁeld. Now only clinical trials can lead to optimization
of it. Adult stem cell therapies should therefore precede
randomized, placebo-controlled double-blind clinical trials.
Another compelling argument for initiating clinical research
is that the resultsof these investigations oftenprovide pivotal
insights that allow a new ﬁeld to advance. For now, the
main challenge is to improve the translation of cellular and
molecular concepts into clinically relevant endpoints so that
stem cell therapy in conjunction with current treatment
modalities may help to further reduce the mortality and
improve the quality of life in MI patients.
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